

## Supplementary Materials

# Thermodynamic Study of Oxidovanadium(IV) with Kojic Acid Derivatives: A Multi-Technique Approach

Rosita Cappai <sup>1,\*</sup>, Guido Crisponi <sup>1</sup>, Daniele Sanna <sup>2</sup>, Valeria Ugone <sup>2</sup>, Andrea Melchior <sup>3</sup>, Eugenio Garribba <sup>4</sup>, Massimiliano Peana <sup>4</sup>, Maria Antonietta Zoroddu <sup>4</sup> and Valeria Marina Nurchi <sup>1,\*</sup>

<sup>1</sup> Dipartimento di Scienze della Vita e dell'Ambiente, Università di Cagliari; 09042 Monserrato-Cagliari, Italy; crisponi@unica.it (G.C.)

<sup>2</sup> Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Trav. La Crucca 3, 07100 Sassari, Italy; daniele.sanna@cnr.it (D.S.); valeria.ugone@cnr.it (V.U.)

<sup>3</sup> DPIA, Laboratorio di Scienze e Tecnologie Chimiche, Università di Udine, Via del Cotonificio 108, 33100 Udine, Italy; andrea.melchior@uniud.it

<sup>4</sup> Dipartimento di Chimica e Farmacia, Università di Sassari, via Vienna 2, 07100 Sassari, Italy; garribba@uniss.it (E.G.); peana@uniss.it (M.P.); zoroddu@uniss.it (M.A.Z.)

\* Correspondence: cappai@unica.it (R.C.); nurchi@unica.it (V.M.N.)

**Citation:** Cappai, R.; Crisponi, G.; Sanna, D.; Ugone, V.; Melchior, A.; Garribba, E.; Peana, M.; Zoroddu, M.A.; Nurchi, V.M. Thermodynamic Study of Oxidovanadium(IV) with Kojic Acid Derivatives: A Multi-Technique Approach. *Pharmaceutics* **2021**, *14*, x. <https://doi.org/10.3390/xxxxx>

Academic Editor: Micheline Draye  
and Mary J. Meegan

Received: 2 September 2021  
Accepted: 7 October 2021  
Published: date

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.




**Copyright:** © 2021 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).


**Table S1.** Species identified in the ESI-MS spectra of the L4 and L9 ligands.

| Species              | Composition   | m/z (exptl) <sup>a</sup> | m/z (calcd) <sup>a</sup> | Deviation (ppm) <sup>b</sup> |
|----------------------|---|--------------------------|--------------------------|------------------------------|
| [L4+H] <sup>+</sup>  | C <sub>15</sub> H <sub>18</sub> NO <sub>8</sub>               | 340.10250                | 340.10269                | -0.6                         |
| [L4+Na] <sup>+</sup> | C <sub>15</sub> H <sub>17</sub> NO <sub>8</sub> Na            | 362.08446                | 362.08464                | -0.5                         |
| [L9+H] <sup>+</sup>  | C <sub>20</sub> H <sub>29</sub> O <sub>8</sub> N <sub>2</sub> | 425.19134                | 425.19184                | -1.2                         |


<sup>a</sup> Experimental and calculated m/z values refer to the monoisotopic peak with the highest intensity. <sup>b</sup> Error in ppm respect to the experimental value, calculated as  $10^6 \times [\text{Experimental (m/z)} - \text{Calculated (m/z)}] / \text{Calculated (m/z)}$ .




**Figure S1.** ESI-MS/MS(+) spectrum of the signal relative to the [L9+3H]<sup>+</sup> ion selected in the range of  $m/z = 425.19 \pm 0.5$ , NCE = 10, recorded on the system V<sup>IV</sup>O<sup>2+</sup>-L9 at 1:1 V<sup>IV</sup>O<sup>2+</sup>:ligand molar ratio at ligand concentration 5 μM (MeOH).




**Figure S2.** ESI-MS/MS(+) spectrum of the signal relative to the [L4+H]<sup>+</sup> ion selected in the range of  $m/z = 340.10 \pm 0.5$ , NCE = 10, recorded on the system V<sup>IV</sup>O<sup>2+</sup>-L4 at 1:1 V<sup>IV</sup>O<sup>2+</sup>:ligand molar ratio with [L4] = 50 μM.




**Figure S3.** Representative spectra of UV titration of L4 ligand at ligand concentration  $3 \times 10^{-4}$  M. Top: beginning of titration at  $\lambda = 274$  nm and pH 3.89. Bottom: end of titration at  $\lambda = 326$  nm and pH = 10.06.




*Figure S4.* Molar absorptivity of L4 ligand.




**Figure S5.** Representative spectra of UV titration of L9 ligand at ligand concentration  $3 \times 10^{-4}$  M. Top: beginning of titration at  $\lambda = 276$  nm and pH 4.87. Bottom: end of titration at  $\lambda = 330$  nm and pH = 10.99.




**Figure S6.** Molar absorptivity of L9 ligand.




**Figure S7.** UV titration of  $\text{V}^{\text{IV}}\text{O}^{2+}\text{-L4}$  at 1:1  $\text{V}^{\text{IV}}\text{O}^{2+}\text{:ligand}$  molar ratio at ligand concentration  $3 \times 10^{-4}$  M. HypSpec screenshot. Top:  $\lambda = 272$  nm, pH 3.33. Middle:  $\lambda = 322$  nm, pH 7.00. Bottom:  $\lambda = 322$  nm, pH 9.98.




**Figure S8.** Molar absorptivity of  $\text{V}^{\text{IV}}\text{O}^{2+}$ -L4 at 1:1  $\text{V}^{\text{IV}}\text{O}^{2+}$ :ligand molar ratio at ligand concentration  $3 \times 10^{-4}$  M.




**Figure S9.** UV titration of  $\text{V}^{\text{IV}}\text{O}^{2+}$ -L4 at 1:2  $\text{V}^{\text{IV}}\text{O}^{2+}$ :ligand molar ratio at ligand concentration  $3 \times 10^{-4}$  M: HypSpec screenshot.  $\lambda = 320$  nm, pH 9.00.




**Figure S10.** UV titration of  $\text{V}^{\text{IV}}\text{O}^{2+}\text{-L4}$  at 1:4  $\text{V}^{\text{IV}}\text{O}^{2+}\text{:ligand}$  molar ratio at ligand concentration  $3 \times 10^{-4}$  M: HypSpec screenshot.  $\lambda = 322$  nm, pH 8.71.




**Figure S11.** UV titration of  $\text{V}^{\text{IV}}\text{O}^{2+}$ -L9 at 1:1  $\text{V}^{\text{IV}}\text{O}^{2+}$ :ligand molar ratio at ligand concentration  $3 \times 10^{-4}\text{M}$ : HypSpec screenshot. Top:  $\lambda = 276 \text{ nm}$ , pH 2.51. Middle:  $\lambda = 276 \text{ nm}$ , pH 7.00. Bottom:  $\lambda = 322 \text{ nm}$ , pH 9.98.




**Figure S12.** Molar absorptivity of  $\text{V}^{\text{IV}}\text{O}^{2+}$ -L9 at 1:1  $\text{V}^{\text{IV}}\text{O}^{2+}$ :ligand molar ratio at ligand concentration  $3 \times 10^{-4}$  M.




**Figure S13.** Molar absorptivity of  $\text{V}^{\text{IV}}\text{O}^{2+}$ -L9 at 1:1  $\text{V}^{\text{IV}}\text{O}^{2+}$ :ligand molar ratio at ligand concentration  $3 \times 10^{-4}$  M.




**Figure S14.** UV titration of  $\text{V}^{\text{IV}}\text{O}^{2+}$ -L9 at 1:4  $\text{V}^{\text{IV}}\text{O}^{2+}$ :ligand molar ratio at ligand concentration  $3 \times 10^{-4}$  M: HypSpec screenshot.  $\lambda = 364$  nm, pH 8.38.




**Figure S15.** Experimental (top) and calculated (bottom) isotopic pattern for the peak of  $[(\text{V}^{\text{IV}}\text{O})_2(\text{L4})_2+2\text{H}]^{2+}$  detected in the ESI-MS(+) spectrum of the system  $\text{V}^{\text{IV}}\text{O}^{2+}$ -L4 at 1:1 molar ratio (LC-MS  $\text{H}_2\text{O}$ , ligand concentration  $50 \mu\text{M}$ ).




**Figure S16.** Experimental (top) and calculated (bottom) isotopic pattern for the peak of  $[(\text{V}^{\text{IV}}\text{O})_2(\text{L}4)_2+\text{H}]^+$  detected in the ESI-MS(+) spectrum of the system  $\text{V}^{\text{IV}}\text{O}^{2+}$ -L4 at 1:1 molar ratio (LC-MS  $\text{H}_2\text{O}$ , ligand concentration  $5 \mu\text{M}$ ).




**Figure S17.** ESI-MS(+) spectrum recorded on the system  $\text{V}^{\text{IV}}\text{O}^{2+}$ -L9 at 1:1 molar ratio (LC-MS  $\text{MeOH}$ , ligand concentration  $5 \mu\text{M}$ ).




**Figure S18.** Experimental (top) and calculated (bottom) isotopic pattern for the peak of  $[(\text{V}^{\text{IV}}\text{O})_2(\text{L}9)_2+2\text{H}]^{2+}$  detected in the ESI-MS(+) spectrum of the system  $\text{V}^{\text{IV}}\text{O}^{2+}$ -L9 at 1:1 molar ratio (LC-MS  $\text{MeOH}$ , ligand concentration  $5 \mu\text{M}$ ).




**Figure S19.** Experimental (top) and calculated (bottom) isotopic pattern for the peak of  $[(\text{V}^{\text{IV}}\text{O})_2(\text{L9})_2+\text{H}]^+$  detected in the ESI-MS(+) spectrum of the system  $\text{V}^{\text{IV}}\text{O}^{2+}$ -L9 at 1:1 molar ratio (LC-MS MeOH, ligand concentration 5  $\mu\text{M}$ ).




**Figure S20.** Experimental (top) and calculated (bottom) isotopic pattern for the peak of  $[(\text{V}^{\text{V}_2}\text{O}_3)(\text{V}^{\text{IV}}\text{O}_2)_2(\text{L9})_4+3\text{H}]^{3+}$  detected in the ESI-MS(+) spectrum of the system  $\text{V}^{\text{IV}}\text{O}^{2+}$ -L9 at 1:1 molar ratio (LC-MS H<sub>2</sub>O, ligand concentration 50  $\mu\text{M}$ ).




**Figure S21.** 1D  $^1\text{H}$ NMR spectra of free ligands L4 (bottom) and L9 (top) in  $\text{MeOD}$ .



**Figure S22.** NMR HSQC of L4 and L9 ligands in  $\text{MeOD}$ .



**Figure S23.** 1D <sup>1</sup>H NMR spectra of L4-V<sup>IV</sup>O<sup>2+</sup> system in MeOD at different L4:V<sup>IV</sup>O<sup>2+</sup> ratios.



**Figure S24.** Comparison of 2D <sup>1</sup>H-<sup>1</sup>H NMR COSY spectra of L4 free (blue) and L4-V<sup>IV</sup>O<sup>2+</sup> (red) systems in MeOD solution.